JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2005; 46:1651-1658, doi:10.1016/j.jacc.2005.01.069
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (66)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strauer, B. E.
Right arrow Articles by Köstering, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strauer, B. E.
Right arrow Articles by Köstering, M.
Related Collections
Right arrowRelated Article

Regeneration of Human Infarcted Heart Muscle by Intracoronary Autologous Bone Marrow Cell Transplantation in Chronic Coronary Artery Disease

The IACT Study

Bodo E. Strauer, MD*,*, Michael Brehm, MD*, Tobias Zeus, MD*, Thomas Bartsch, MD*, Christina Schannwell, MD*, Christine Antke, MD{dagger}, Rüdiger V. Sorg, PhD{ddagger}, Gesine Kögler, PhD{ddagger}, Peter Wernet, MD{ddagger}, Hans-Wilhelm Müller, MD{dagger} and Matthias Köstering, MD*

* Department of Internal Medicine, Division of Cardiology, Pneumology and Angiology, Heinrich-Heine-University, Düsseldorf, Germany
{dagger} Department of Nuclear Medicine, Heinrich-Heine-University, Düsseldorf, Germany
{ddagger} Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine-University, Düsseldorf, Germany



View larger version (24K):

[in a new window]
 
Figure 1 Diagrammatic representation of the algorithm of intracoronary stem cell therapy (Tx) in chronic ischemic heart disease after myocardial infarction. The infarcts occurred 27 ± 31 months before Tx. All infarct patients were treated with percutaneous transluminal coronary angioplasty (PTCA) or with stent implantation. 9 ± 6 months before (investigation 1) coronary angiography (including quantitative left ventriuclography) was performed. If re-stenosis was present, re-PTCA was made. Investigation 2 embraces all patients for the evaluation of coronary morphology after PTCA/stent. Only patients with an open infarct-related artery were included in both groups. Patients who agreed to Tx received within 10 days after investigation 2 bone marrow punctures and Tx by the intracoronary administration route and had altogether five invasive investigations, including two for therapeutic reasons (nos. 0 and 1). Patients who were not eligible for Tx (disagreement with bone marrow puncture and with subsequent Tx) served as a control group. Investigation 3 represents all follow-up measurements 3 months after Tx (Tx patients) or after investigation 2 for control group patients.

 


View larger version (40K):

[in a new window]
 
Figure 2 Representative illustration of 18F-FDG-positron emission tomography (PET) before (above) and 3 months after (below) cell therapy in the transversal (left) and longitudinal (right projection) in a 30-year-old male patient with an 8-month-old anteroapical infarction. Note the restoration of glucose uptake (below) within the infarcted area of the formerly completely avital anteroapical myocardium.

 


View larger version (37K):

[in a new window]
 
Figure 3 Illustration of the mean values of (A) area of infarction, (B) ejection fraction, and (C) infarction wall movement velocity, determined by quantitative left ventriculography in both groups (control group vs. transplantation [Tx] group) at the point of time: investigations 1, 2, and 3. Comparision of both groups with chronically infarcted myocardium (conrol group vs. Tx group), n = 18 patients. Investigation 1 was 9 ± 6 months before cell transplantation (controls: 9 ± 5 months before percutaneous transluminal coronary angioplasty [PTCA]); investigation 2 within 10 days before cell tranplantation (controls: at the time point of PTCA) and investigation 3 was three months after cell transplantation (controls: 8 ± 5 months after PTCA). Note the significant decrease of infarct size and the increase in ejection fraction and in contractility (infarction wall movement velocity) 3 months after cell therapy in comparison with the control group. *p = not significant (investigation 2 vs. investigation 3); #p = 0.001 (investigation 2 vs. investigation 3).

 


View larger version (12K):

[in a new window]
 
Table 4 Positron Emission Tomography and Spiroergometry Before and After Stem Cell Therapy in Chronically Infarcted Myocardium

 





HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2005 by the American College of Cardiology Foundation.